These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Polio eradication. Rethinking the polio endgame. Roberts L Science; 2009 Feb; 323(5915):705. PubMed ID: 19197036 [No Abstract] [Full Text] [Related]
9. Decision analysis in planning for a polio outbreak in the United States. Jenkins PC; Modlin JF Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814 [TBL] [Abstract][Full Text] [Related]
10. Polio eradication in India: how far are we from reaching the goal? Banerjee K; Sahu S; Bandyopadhyay S Indian J Pediatr; 2001 Mar; 68 Suppl 1():S6-14. PubMed ID: 11411387 [No Abstract] [Full Text] [Related]
11. AAFP childhood immunization update. AAFP Commission on Clinical Policies and Research. Am Fam Physician; 1998 Jan; 57(1):158. PubMed ID: 9447221 [No Abstract] [Full Text] [Related]
12. Polio immunization policy in Mexico: economic assessment of current practice and future alternatives. Mascareñas A; Salinas J; Tasset-Tisseau A; Mascareñas C; Khan MM Public Health; 2005 Jun; 119(6):542-9. PubMed ID: 15826896 [TBL] [Abstract][Full Text] [Related]
13. Studies on immunization with inactivated and liver poliovirus vaccines. Böttiger M Acta Paediatr Scand; 1966; ():Suppl 164:1-42. PubMed ID: 5326196 [No Abstract] [Full Text] [Related]
14. Monitoring vaccines for human oncogenicity--discussion. Robbins FC Natl Cancer Inst Monogr; 1968 Dec; 29():457-8. PubMed ID: 4305437 [No Abstract] [Full Text] [Related]
15. Time for changes in immunization: inactivated poliovirus vaccine and a family practice immunization book. Zimmerman RK J Fam Pract; 1999 Aug; 48(8):588-9. PubMed ID: 10496636 [No Abstract] [Full Text] [Related]
16. The costs of future polio risk management policies. Tebbens RJ; Sangrujee N; Thompson KM Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394 [TBL] [Abstract][Full Text] [Related]
17. Oral polio vaccines and their role in polio eradication in India. Paul Y Expert Rev Vaccines; 2009 Jan; 8(1):35-41. PubMed ID: 19093771 [TBL] [Abstract][Full Text] [Related]
18. Oral polio vaccine and human cancer: a reassessment of SV40 as a contaminant based upon legal documents. Kops SP Anticancer Res; 2000; 20(6C):4745-9. PubMed ID: 11205211 [TBL] [Abstract][Full Text] [Related]
19. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180 [TBL] [Abstract][Full Text] [Related]
20. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Yang C; Shi H; Zhou J; Liang Y; Xu H Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]